Results 31 to 40 of about 101,700 (245)

Integrating microfluidics and biosensing on a single flexible acoustic device using hybrid modes [PDF]

, 2020
Integration of microfluidics and biosensing functionalities on a single device holds promise in continuous health monitoring and disease diagnosis for point-of-care applications.
Dodd, Linzi, Fu, Richard, Luo, Jing-ting, McHale, Glen, Reboud, Julien, Tao, Kai, Tao, Ran, Todryk, Stephen, Torun, Hamdi, Wu, Qiang, Yang, Xin   +10 more
core   +5 more sources

Determination of the Cut-off Value for Imatinib Plasma Levels Linked to Occurrence of Bone Pain in CML Patients

Drug Design, Development and Therapy, 2022
Marwa S Hamza,1 Samia A Shouman,2 Raafat Abdelfattah,3 Heba S Moussa,4 Mervat M Omran2 1Clinical Pharmacy Practice Department, Faculty of Pharmacy, The British University in Egypt, El-Sherouk City, Cairo, Egypt; 2Pharmacology Unit, Cancer Biology ...
Hamza MS, Shouman SA, Abdelfattah R, Moussa HS, Omran MM   +4 more
doaj  

Lack of Association between C1236T, G2677T/A and C3435T Variants of the ABCB1 Gene and Imatinib Response in Iranian Chronic Myeloid Leukemia Patients [PDF]

Journal of Sciences, Islamic Republic of Iran, 2021
Imatinib introduction caused to improve the clinical outcomes of chronic myeloid leukemia (CML) patients. Despite the significant effects of Imatinib, pharmacogenetic variables induced treatment resistant is also observed.
Maedeh Khosravi, Zahra Khalaj, Negar Nouri, Malihe Najaflu, Valiollah Mehrzad, Mohammad Forat-Yazdi, Fariborz Mokarian, Mansour Salehi   +7 more
doaj   +1 more source

Imatinib Mesylate Reduces Neurotrophic Factors and pERK and pAKT Expression in Urinary Bladder of Female Mice With Cyclophosphamide-Induced Cystitis

Frontiers in Systems Neuroscience, 2022
Imatinib mesylate is a tyrosine kinase inhibitor that inhibits platelet-derived growth factor receptor (PDGFR)-α, -β, stem cell factor receptor (c-KIT), and BCR-ABL.
Megan Perkins, Beatrice M. Girard, Susan E. Campbell, Grant W. Hennig, Margaret A. Vizzard   +4 more
doaj   +1 more source

Evaluation of the anticancer activity of dipyridamole and Imatinib mesylate compounds against breast cancer cell line and related biochemical and genetic changes [PDF]

Journal of Bioscience and Applied Research, 2021
Imatinib mesylate and dipyridamole were antineoplastic targeted chemotherapeutic agents, and it is here evaluating the anticancer of imatinib mesylate and dipyridamole compounds against MDA-MB231 breast cancer cell line in-vitro and the related cell ...
Rania El-Leithy, Aly Mohamed, Asmaa EL-refaay, Mohamed Omran   +3 more
doaj   +1 more source

Treatment dilemmas in patients with gastrointestinal stromal tumors (GIST) who experienced imatinib-induced pneumonitis: A case series

Current Problems in Cancer: Case Reports
Introduction: Imatinib has led to a phenomenal progress in the treatment of GIST. A rare and lesser-known side effect of imatinib is pneumonitis, an uncommon multicausal interstitial lung disease.
Deborah van de Wal, Evelyne Roets, Roos F. Bleckman, Jorn Nützinger, Birthe C. Heeres, J. Martijn Kerst, Mahmoud Mohammadi, Anna K.L. Reyners, Ingrid M.E. Desar, Astrid W. Oosten, Neeltje Steeghs, Winette T.A. van der Graaf   +11 more
doaj   +1 more source

Nilotinib, an approved leukemia drug, inhibits smoothened signaling in Hedgehog-dependent medulloblastoma. [PDF]

, 2019
Dysregulation of the seven-transmembrane (7TM) receptor Smoothened (SMO) and other components of the Hedgehog (Hh) signaling pathway contributes to the development of cancers including basal cell carcinoma (BCC) and medulloblastoma (MB).
Abagyan, Ruben, Chahal, Kirti Kandhwal, Chen, Clark C, Durden, Donald L, Kufareva, Irina, Li, Jie, Parle, Milind, Wechsler-Reya, Robert J   +7 more
core   +1 more source

Identifying and validating a combined mRNA and microRNA signature in response to imatinib treatment in a chronic myeloid leukemia cell line. [PDF]

PLoS ONE, 2014
Imatinib, a targeted tyrosine kinase inhibitor, is the gold standard for managing chronic myeloid leukemia (CML). Despite its wide application, imatinib resistance occurs in 20-30% of individuals with CML.
Steven Bhutra, Divya Lenkala, Bonnie LaCroix, Meng Ye, R Stephanie Huang   +4 more
doaj   +1 more source

Imatinib Optimized Therapy Improves Major Molecular Response Rates in Patients with Chronic Myeloid Leukemia

Pharmaceutics, 2022
The registered dose for imatinib is 400 mg/d, despite high inter-patient variability in imatinib plasmatic exposure. Therapeutic drug monitoring (TDM) is routinely used to maximize a drug’s efficacy or tolerance.
Hyacinthe Johnson-Ansah, Benjamin Maneglier, Françoise Huguet, Laurence Legros, Martine Escoffre-Barbe, Martine Gardembas, Pascale Cony-Makhoul, Valérie Coiteux, Laurent Sutton, Wajed Abarah, Camille Pouaty, Jean-Michel Pignon, Bachra Choufi, Sorin Visanica, Bénédicte Deau, Laure Morisset, Emilie Cayssials, Mathieu Molimard, Stéphane Bouchet, François-Xavier Mahon, Franck Nicolini, Philippe Aegerter, Jean-Michel Cayuela, Marc Delord, Heriberto Bruzzoni-Giovanelli, Philippe Rousselot   +25 more
doaj   +1 more source

Excellent outcomes of 2G-TKI therapy after imatinib failure in chronic phase CML patients [PDF]

, 2018
open25noSecond-generation tyrosine kinase inhibitors (2G-TKIs) dasatinib and nilotinib produced historical rates of about 50% complete cytogenetic response (CCyR) and about 40% major molecular response (MMR) in chronic myeloid leukaemia (CML) patients ...

core   +1 more source